SNNAQ SEC Filings - Sienna Biopharmaceuticals, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

1656328

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sienna Biopharmaceuticals, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

February 14, 2020	SC 13G/A	SNNA / Sienna Biopharmaceuticals, Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Sienna Biopharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 82622H108 (CUSIP Number) December 31, 2019 Date of Event Whi
December 11, 2019	15-12B	SNNA / Sienna Biopharmaceuticals, Inc. 15-12B - - 15-12B 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38155 Sienna Biopharmaceuticals, Inc. (Exact name of registrant
December 11, 2019	S-8 POS	SNNA / Sienna Biopharmaceuticals, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on December 11, 2019 Registration No.
December 11, 2019	S-8 POS	SNNA / Sienna Biopharmaceuticals, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on December 11, 2019 Registration No.
December 11, 2019	POS AM	SNNA / Sienna Biopharmaceuticals, Inc. POS AM - - POS AM POS AM As filed with the Securities and Exchange Commission on December 11, 2019 Registration No.
December 11, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2019 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporatio
December 11, 2019	S-8 POS	SNNA / Sienna Biopharmaceuticals, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on December 11, 2019 Registration No.
November 15, 2019	EX-99.2	Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures — Bids due on December 2, 2019 by 5:00 p.m. Eastern Time EX-99.2 3 d836381dex992.htm EX-99.2 Exhibit 99.2 Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures — Bids due on December 2, 2019 by 5:00 p.m. Eastern Time WESTLAKE VILLAGE, Calif., Nov. 14, 2019 – Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 13, 2019, the United States
November 15, 2019	EX-99.1	Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice — Sienna’s common stock to remain conditionally listed during the Chapter 11 asset sale process EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice — Sienna’s common stock to remain conditionally listed during the Chapter 11 asset sale process WESTLAKE VILLAGE, Calif., Nov. 14, 2019 – Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 12, 2019, the Nasda
November 15, 2019	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporatio
November 12, 2019	EX-10.5	Key Employee Incentive Bonus Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Frederick C. Beddingfield III, dated as of September 11, 2019. EX-10.5 EXHIBIT 10.5 30699 Russell Ranch Road, Suite 140, Westlake Village, CA 91362 September 11, 2019 Frederick C. Beddingfield, III Re: Incentive Bonus Dear Frederick: As you know, the board of directors (the “Board”) of Sienna Biopharmaceuticals, Inc. (the “Company”) may authorize the Company to proceed with a chapter 11 bankruptcy (the “Reorganization”). To encourage you to remain committed t
November 12, 2019	EX-10.3	Management Retention Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Paul Lizzul, dated as of September 11, 2019. EX-10.3 EXHIBIT 10.3 30699 Russell Ranch Road, Suite 140, Westlake Village, CA 91362 September 11, 2019 Paul Lizzul Re: Retention Bonus Dear Paul: As you know, the board of directors (the “Board”) of Sienna Biopharmaceuticals, Inc. (the “Company”) may authorize the Company to proceed with a chapter 11 bankruptcy (the “Reorganization”). In connection with the Reorganization, we are offering you the
November 12, 2019	EX-10.2	Management Retention Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Alexander Azoy, dated as of September 11, 2019. EX-10.2 EXHIBIT 10.2 30699 Russell Ranch Road, Suite 140, Westlake Village, CA 91362 September 11, 2019 Alexander Azoy Re: Retention Bonus Dear Alex: As you know, the board of directors (the “Board”) of Sienna Biopharmaceuticals, Inc. (the “Company”) may authorize the Company to proceed with a chapter 11 bankruptcy (the “Reorganization”). In connection with the Reorganization, we are offering you
November 12, 2019	EX-10.7	Key Employee Incentive Bonus Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Paul Lizzul, dated as of September 11, 2019. EX-10.7 EXHIBIT 10.7 30699 Russell Ranch Road, Suite 140, Westlake Village, CA 91362 September 11, 2019 Paul Lizzul Re: Incentive Bonus Dear Paul: As you know, the board of directors (the “Board”) of Sienna Biopharmaceuticals, Inc. (the “Company”) may authorize the Company to proceed with a chapter 11 bankruptcy (the “Reorganization”). To encourage you to remain committed to the success of the Com
November 12, 2019	EX-10.8	Key Employee Incentive Bonus Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Timothy K. Andrews, dated as of September 11, 2019. EX-10.8 9 d811583dex108.htm EX-10.8 EXHIBIT 10.8 30699 Russell Ranch Road, Suite 140, Westlake Village, CA 91362 September 11, 2019 Timothy Andrews Re: Incentive Bonus Dear Tim: As you know, the board of directors (the “Board”) of Sienna Biopharmaceuticals, Inc. (the “Company”) may authorize the Company to proceed with a chapter 11 bankruptcy (the “Reorganization”). To encourage you to remain comm
November 12, 2019	EX-10.4	Management Retention Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Timothy K. Andrews, dated as of September 11, 2019. EX-10.4 5 d811583dex104.htm EX-10.4 EXHIBIT 10.4 30699 Russell Ranch Road, Suite 140, Westlake Village, CA 91362 September 11, 2019 Timothy K. Andrews Re: Retention Bonus Dear Tim: As you know, the board of directors (the “Board”) of Sienna Biopharmaceuticals, Inc. (the “Company”) may authorize the Company to proceed with a chapter 11 bankruptcy (the “Reorganization”). In connection with the Reorg
November 12, 2019	EX-10.10	Separation and General Release Agreement by and between Sienna Biopharmaceuticals, Inc. and Diane Stroehmann, dated as of August 1, 2019 EX-10.10 Exhibit 10.10 SEPARATION AND GENERAL RELEASE AGREEMENT I, Diane Stroehmann, enter into this Separation and General Release Agreement (“Agreement”) with Sienna Biopharmaceuticals, Inc., a Delaware Corporation (the “Company”), as of the Effective Date, which is the eighth (8th) day after the date on which I sign this Agreement. WHEREAS, I am employed by the Company pursuant to that certain
November 12, 2019	EX-10.9	Key Employee Retention Plan EX-10.9 EXHIBIT 10.9 SIENNA BIOPHARMACEUTICALS, INC. KEY EMPLOYEE RETENTION PLAN 1. Purpose. The purpose of this Key Employee Retention Plan (the “Plan”) is to encourage eligible employees of Sienna Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), to continue their employment with the Company following the commencement by the Company of a case under chapter 11 of the U.S. Bankrupt
November 12, 2019	EX-10.6	Key Employee Incentive Bonus Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Alexander Azoy, dated as of September 11, 2019. EX-10.6 EXHIBIT 10.6 30699 Russell Ranch Road, Suite 140, Westlake Village, CA 91362 September 11, 2019 Alexander Azoy Re: Incentive Bonus Dear Alex: As you know, the board of directors (the “Board”) of Sienna Biopharmaceuticals, Inc. (the “Company”) may authorize the Company to proceed with a chapter 11 bankruptcy (the “Reorganization”). To encourage you to remain committed to the success of the
November 12, 2019	EX-10.1	Management Retention Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Frederick C. Beddingfield III, dated as of September 11, 2019. EX-10.1 EXHIBIT 10.1 30699 Russell Ranch Road, Suite 140, Westlake Village, CA 91362 September 11, 2019 Frederick C. Beddingfield, III Re: Retention Bonus Dear Frederick: As you know, the board of directors (the “Board”) of Sienna Biopharmaceuticals, Inc. (the “Company”) may authorize the Company to proceed with a chapter 11 bankruptcy (the “Reorganization”). In connection with the Reorganization,
November 12, 2019	10-Q	Quarterly Report - 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 17, 2019	EX-99.1	Case 19-12051-MFW Doc 116 Filed 10/11/19 Page 1 of 4 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE ------------------------------------------------------------------------------ x : In re: : Chapter 11 : SIENNA BIOPHARMACEUTICALS EX-99.1 Exhibit 99.1 Case 19-12051-MFW Doc 116 Filed 10/11/19 Page 1 of 4 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - x : In re: : Chapter 11 : SIENNA BIOPHARMACEUTICALS, INC., : Case No. 19-12051 (MFW) : Debtor.1 : : Ref. Docket Nos. 6, 40, 101 - x NOTICE OF FINAL ORDER (I) ESTABLISHING NOTICE AND HEARING PROCEDURES FOR TRADING OF SIENNA EQUITY SECURITIES AND (II) GRANTIN
October 17, 2019	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2019 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation
September 23, 2019	EX-99.1	IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE ----------------------------------------------------------------------------- In re: SIENNA BIOPHARMACEUTICALS, INC., Debtor.1 -------------------------------------------------------- EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - In re: SIENNA BIOPHARMACEUTICALS, INC., Debtor.1 - x : : : : : : : : x Chapter 11 Case No. 19-12051 (MFW) Objection Deadline: October 8, 2019 at 4:00 p.m. (ET) Hearing Date: October 15, 2019 at 11:30 a.m. (ET) Docket Ref. No. 40 NOTICE OF INTERIM ORDER (I) ESTABLISHING NOTICE AND HEARING PROCEDURES FOR TRADIN
September 23, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2019 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporati
September 17, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Bankruptcy or Receivership 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2019 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporati
August 14, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2019 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation)
August 8, 2019	EX-10.1	Non-Employee Director Compensation Program, as amended and restated effective May 30, 2019. EX-10.1 2 d701234dex101.htm EX-10.1 Exhibit 10.1 SIENNA BIOPHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (AS AMENDED AND RESTATED EFFECTIVE MAY 30, 2019) This Sienna Biopharmaceuticals, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2017 Incentive Award Plan (the “Plan”) and became effective upon the closing
August 8, 2019	10-Q	SNNA / Sienna Biopharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38155 Sienn
June 3, 2019	8-K	Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2019 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation) (C
May 8, 2019	EX-99.1	Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results — Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis EX-99.1 2 d730501dex991.htm EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results — Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis WESTLAKE VILLAGE, Calif., May 8, 2019 – Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today reported the Company’s financial results for the first quarter of 2019. “We are pleased to report the
May 8, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2019 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation) (Co
May 8, 2019	EX-10.2	Employment Agreement by and between Sienna Biopharmaceuticals, Inc. and Alexander Azoy, dated as of March 21, 2019. EX-10.2 2 d694118dex102.htm EX-10.2 Exhibit 10.2 SIENNA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), is made by and between Sienna Biopharmaceuticals, Inc., a Delaware corporation (the “Company”) and Alexander Azoy (“Executive” and, together with the Company, the “Parties”), effective as of April 1, 2019 (the “Effective Date”). This Agreement supersede
May 8, 2019	10-Q	SNNA / Sienna Biopharmaceuticals, Inc. 10-Q Quarterly Report FORM 10-Q FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 8, 2019	EX-10.3	Separation and General Release Agreement by and between Sienna Biopharmaceuticals, Inc. and John W. Smither, dated as of April 1, 2019. EX-10.3 3 d694118dex103.htm EX-10.3 Exhibit 10.3 SEPARATION AND GENERAL RELEASE AGREEMENT I, John W. Smither, enter into this Separation and General Release Agreement (“Agreement”) with Sienna Biopharmaceuticals, Inc., a Delaware Corporation (the “Company”), as of the Effective Date, which is the eighth (8th) day after the date on which I sign this Agreement. WHEREAS, I am employed by the Company
April 11, 2019	DEFA14A	SNNA / Sienna Biopharmaceuticals, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro
April 11, 2019	DEF 14A	SNNA / Sienna Biopharmaceuticals, Inc. DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 21, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2019 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation)
March 14, 2019	S-8	SNNA / Sienna Biopharmaceuticals, Inc. S-8 S-8 As filed with the Securities and Exchange Commission on March 14, 2019 Registration No.
March 14, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2019 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation)
March 14, 2019	EX-99.1	Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results WESTLAKE VILLAGE, Calif., Mar. 14, 2019 – Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today reported the Company’s financial results for the fourth quarter and full year of 2018. “We are pleased to report the results of our 2018 fourth quarter an
March 14, 2019	EX-10.20	Separation Agreement by and between Sienna Biopharmaceuticals, Inc. and Todd Harris, dated as of November 5, 2018. EX-10.20 2 d659927dex1020.htm EX-10.20 Exhibit 10.20 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) is made by and between Todd Harris (“Executive”) and Sienna Biopharmaceuticals, Inc., a Delaware corporation (the “Company” and, together with Executive, the “Parties”) is made effective as of the date Executive signs this Agreement (the “Effective Date”), with reference to the fol
March 14, 2019	10-K	SNNA / Sienna Biopharmaceuticals, Inc. 10-K (Annual Report) 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 14, 2019	EX-21.1	List of Subsidiaries. EX-21.1 Exhibit 21.1 List of Subsidiaries of Sienna Biopharmaceuticals, Inc. Name Jurisdiction of Incorporation or Organization Creabilis Holdings Limited United Kingdom Sienna Biopharmaceuticals S.A. Luxembourg Sienna Biopharmaceuticals S.r.L. Italy Creabilis UK Limited United Kingdom
March 6, 2019	SC 13D	SNNA / Sienna Biopharmaceuticals, Inc. / ARCH Venture Fund VIII, L.P. - ARCH VENTURE FUND VIII, L.P. - SIENNA BIOPHARMACEUTICALS -- SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Sienna Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 82622H108 (CUSIP Number) Mark McDonnell ARCH Venture Corporation 8755 W. Higgins Road Suite 1025 Chicago, IL 60631 (Name, Address and Telephone
February 22, 2019	EX-1.1	Underwriting Agreement, dated as of February 20, 2019, among Sienna Biopharmaceuticals, Inc., Cowen and Company, LLC and BMO Capital Markets Corp., as representative of the underwriters named therein. EX-1.1 2 d689674dex11.htm EX-1.1 Exhibit 1.1 SIENNA BIOPHARMACEUTICALS, INC. 8,000,000 Shares of Common Stock Underwriting Agreement February 20, 2019 Cowen and Company, LLC BMO Capital Markets Corp. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o BMO Capital Markets Corp. 3 Times Square New Yor
February 22, 2019	8-K	Financial Statements and Exhibits, Other Events 8-K 1 d689674d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2019 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdi
February 21, 2019	424B5	8,000,000 Shares Common stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-226595 PROSPECTUS SUPPLEMENT (To prospectus dated August 14, 2018) 8,000,000 Shares Common stock We are offering 8,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “SNNA.” On February 19, 2019, the last reported sale price of our common stock on the Nasdaq
February 19, 2019	424B5	Shares Common stock 424B5 1 d679968d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-226595 This prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. Neither this prospectus supplement nor the accompanying prospectus is an offer to sell these securities, and we are not soliciting an offer t
February 14, 2019	SC 13G/A	SNNA / Sienna Biopharmaceuticals, Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Sienna Biopharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 82622H108 (CUSIP Number) December 31, 2018 Date of Event Whi
February 14, 2019	SC 13G/A	SNNA / Sienna Biopharmaceuticals, Inc. / ARCH Venture Fund VIII, L.P. - ARCH VENTURE FUND VIII, L.P. - SIENNA BIOPHARMACEUTICALS, INC. -- SCHEDULE 13G/A(#1) Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sienna Biopharmaceuticals, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 82622H108 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig
February 8, 2019	EX-99.1	Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System — SNA-001 addresses a large unmet need in laser hair removal by treating light hair using a topical solution o EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System — SNA-001 addresses a large unmet need in laser hair removal by treating light hair using a topical solution of silver photoparticles, an ultra-efficient light absorber — — If cleared, SNA-001 has potential to expand the $3 billion U.S. la
February 8, 2019	8-K	Financial Statements and Exhibits, Other Events 8-K 1 d703775d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2019 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdic
January 30, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 d673952d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2019 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdic
January 30, 2019	EX-4.1	Warrant to Purchase Common Stock, dated as of January 28, 2019, by and between Silicon Valley Bank and Sienna Biopharmaceuticals, Inc. EX-4.1 2 d673952dex41.htm EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTAN
January 30, 2019	EX-4.2	Warrant to Purchase Common Stock, dated as of January 28, 2019, by and between Life Science Loans II, LLC and Sienna Biopharmaceuticals, Inc. EX-4.2 Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COM
January 30, 2019	EX-10.1	First Amendment to Loan and Security Agreement, dated as of January 28, 2019 between Silicon Valley Bank and Sienna Biopharmaceuticals, Inc. EX-10.1 4 d673952dex101.htm EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into this 28th day of January, 2019, by and between SILICON VALLEY BANK (“Bank”) and SIENNA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Borrower”). RECITALS A. Bank and Borrower have entered into that certain Loan a
January 2, 2019	8-K	Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2019 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or Other Jurisdiction of Incorporation
January 2, 2019	EX-99.1	Forward-Looking Statements This presentation contains forward-looking statements. All statements other than descriptions of historical facts contained in this presentation, including statements regarding future operational and financial results and p EX-99.1 Company Overview January 2019 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than descriptions of historical facts contained in this presentation, including statements regarding future operational and financial results and positions, business strategy, prospective products, potential market, commercial opportunity and mar
December 12, 2018	8-K	Other Events 8-K 1 d672339d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2018 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or Other Ju
December 3, 2018	EX-99.2	Forward Looking Statements This presentation contains forward-looking statements. All statements other than descriptions of historical facts contained in this presentation, including statements regarding future operational and financial results and p EX-99.2 SNA-120 Phase 2b Trial Top-Line Results December 3, 2018 March 2017 Exhibit 99.2 Forward Looking Statements This presentation contains forward-looking statements. All statements other than descriptions of historical facts contained in this presentation, including statements regarding future operational and financial results and positions, business strategy, prospective products, potential
December 3, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K 1 d666695d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2018 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or Other Jur
December 3, 2018	EX-99.1	Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019 — 27% of subjects achie EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019 — 27% of subjects achieved 75% reduction in PASI score (PASI 75) vs 13% with vehicle; 29% of subjects achieved two-grade improvement on IGA and ‘clear’
November 8, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2018 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation
November 8, 2018	EX-99.1	Sienna Biopharmaceuticals® Reports Third Quarter 2018 Financial Results EX-99.1 2 d647782dex991.htm EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals® Reports Third Quarter 2018 Financial Results WESTLAKE VILLAGE, Calif., Nov. 8, 2018 – Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today reported the Company’s financial results for the third quarter of 2018. “We are pleased to report the results of our third q
November 8, 2018	10-Q	SNNA / Sienna Biopharmaceuticals, Inc. 10-Q (Quarterly Report) 10-Q 1 d632886d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f
October 3, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2018 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation) (Co
August 27, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K 1 d615409d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2018 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdict
August 27, 2018	EX-99.1	Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2 — Phase 1/2 study data of SNA-125 in atopic dermatitis on track to be released in fourth quarter of 2018 — SNA-125 Phas EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2 — Phase 1/2 study data of SNA-125 in atopic dermatitis on track to be released in fourth quarter of 2018 — SNA-125 Phase 2 studies expected to begin in second half of 2019 WESTLAKE VILLAGE, Calif., Aug. 27, 2018 – Sienna Biopharmaceuticals, Inc. (N
August 23, 2018	424B5	$75,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-226595 PROSPECTUS SUPPLEMENT (To prospectus dated August 14, 2018) $75,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreem
August 10, 2018	CORRESP	SNNA / Sienna Biopharmaceuticals, Inc. CORRESP CORRESP Sienna Biopharmaceuticals, Inc. 30699 Russell Ranch Road, Suite 140 Westlake Village, California 91362 August 10, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Irene Paik Re: Sienna Biopharmaceuticals, Inc. Registration Statement on Form S-3 (Registration No. 333-226595) Ladies and Gentlemen: In accordan
August 9, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2018 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporat
August 9, 2018	EX-99.1	Sienna Biopharmaceuticals Reports Second Quarter 2018 Financial Results EX-99.1 2 d600363dex991.htm EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals Reports Second Quarter 2018 Financial Results WESTLAKE VILLAGE, Calif., Aug. 9, 2018 – Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today reported the Company’s financial results for the second quarter of 2018. “We are pleased to report the results of a busy sec
August 9, 2018	10-Q	SNNA / Sienna Biopharmaceuticals, Inc. 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 3, 2018	EX-12.1	Statement Regarding the Computation of Ratio of Earnings to Combined Fixed Charges and Preferred Stock Dividends. EX-12.1 Exhibit 12.1 STATEMENT REGARDING THE COMPUTATION OF RATIOS Our earnings are inadequate to cover combined fixed charges and preference dividends. The following table sets forth the dollar amount of the deficiency (in thousands) to cover fixed charges for the periods indicated. Three Months Ended March 31, Year Ended December 31, 2018 2017 2016 2015 EARNINGS: Net loss before taxes $ (17,103
August 3, 2018	S-3	SNNA / Sienna Biopharmaceuticals, Inc. S-3 Table of Contents As filed with the Securities and Exchange Commission on August 3, 2018 Registration No.
August 3, 2018	EX-1.2	Sales Agreement, dated August 3, 2018, by and between Sienna Biopharmaceuticals, Inc. and Cowen and Company, LLC. EX-1.2 2 d591599dex12.htm EX-1.2 Exhibit 1.2 SIENNA BIOPHARMACEUTICALS, INC. $75,000,000 COMMON STOCK SALES AGREEMENT August 3, 2018 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Sienna Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and
August 3, 2018	EX-4.4	Form of Indenture. EX-4.4 Exhibit 4.4 SIENNA BIOPHARMACEUTICALS, INC. INDENTURE Dated as of , 20 Wilmington Trust, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Secti
August 3, 2018	EX-25.1	Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of Wilmington Trust, National Association, as trustee under the indenture filed herewith. EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 ☐ Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) WILMINGTON TRUST, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) 16-1486454 (I.R.S. employer identification no.) 1100 North Market Street Wilmington, DE 19890-0001 (Address of pr
August 2, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2018 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation) (
July 30, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2018 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation) (
July 30, 2018	EX-99.2	Forward Looking Statements This presentation contains forward-looking statements. All statements other than descriptions of historical facts contained in this presentation, including statements regarding future operational and financial results and p EX-99.2 SNA-001 Acne Pivotal Trials: Results with 1064 nm and 810 nm Lasers July 30, 2018 March 2017 Exhibit 99.2 Forward Looking Statements This presentation contains forward-looking statements. All statements other than descriptions of historical facts contained in this presentation, including statements regarding future operational and financial results and positions, business strategy, prospec
July 30, 2018	EX-99.1	Sienna Biopharmaceuticals Announces Pivotal Trials with SNA-001 in Acne Did Not Meet Primary and Secondary Endpoints — Results from independent pivotal trials with SNA-001 for the reduction of unwanted light-pigmented hair expected beginning in the f EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals Announces Pivotal Trials with SNA-001 in Acne Did Not Meet Primary and Secondary Endpoints — Results from independent pivotal trials with SNA-001 for the reduction of unwanted light-pigmented hair expected beginning in the fourth quarter of 2018 — Sienna continues to advance robust multi-asset pipeline, including SNA-120 and SNA-125 — Company will con
July 24, 2018	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2018 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporati
July 24, 2018	EX-99.1	Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis — SNA-120, a new chemical entity derived from the company’s Topical by Design™ platform, was well tolerated with mini EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis — SNA-120, a new chemical entity derived from the company’s Topical by Design™ platform, was well tolerated with minimal to no detectable systemic exposure — Vast majority of psoriasis patients suffer from itch, yet there are no FDA-approved topi
July 2, 2018	EX-10.1	Loan and Security Agreement, dated as of June 29, 2018 between Silicon Valley Bank and Sienna Biopharmaceuticals, Inc. EX-10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated and effective as of June 29, 2018 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and SIENNA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties
July 2, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2018 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation) (Comm
June 7, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2018 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation) (C
June 7, 2018	EX-99.1	2 Forward Looking Statements This presentation contains forward-looking statements. All statements other than descriptions of historical facts contained in this presentation, including statements regarding future operational and financial results and EX-99.1 Sienna biopharmaceuticals TM Company Overview June 2018 Mar c h 2 0 1 7 Exhibit 99.1 2 Forward Looking Statements This presentation contains forward-looking statements. All statements other than descriptions of historical facts contained in this presentation, including statements regarding future operational and financial results and positions, business strategy, prospective products, pote
June 5, 2018	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2018 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation) (Commi
May 14, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2018 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporatio
May 14, 2018	EX-99.1	Sienna Biopharmaceuticals Reports First Quarter 2018 Financial Results EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals Reports First Quarter 2018 Financial Results WESTLAKE VILLAGE, Calif., May 14, 2018 – Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the first quarter of 2018. “We are pleased to report the results of our first quarter,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Off
May 14, 2018	EX-10.2	Employment Agreement by and between Sienna Biopharmaceuticals, Inc. and John W. Smither, dated as of March 21, 2018 Exhibit 10.2 SIENNA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), is made by and between Sienna Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?) and John Smither (?Executive? and, together with the Company, the ?Parties?), effective as of April 16, 2018 (the ?Effective Date?). WHEREAS, the Company desires to assure itself of the services
May 14, 2018	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0
May 14, 2018	EX-10.1	Separation and General Release Agreement by and between Sienna Biopharmaceuticals, Inc. and Richard D. Peterson, dated as of March 19, 2018. Exhibit 10.1 SEPARATION AND GENERAL RELEASE AGREEMENT I, Richard D. Peterson, enter into this Separation and General Release Agreement (“Agreement”) with Sienna Biopharmaceuticals, Inc., a Delaware Corporation (the “Company”), as of the Effective Date, which is the eighth (8th) day after the date on which I sign this Agreement. WHEREAS, I am employed by the Company pursuant to that certain Employm
April 19, 2018	DEFA14A	SNNA / Sienna Biopharmaceuticals, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro
April 19, 2018	DEF 14A	SNNA / Sienna Biopharmaceuticals, Inc. DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 21, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2018 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporat
March 15, 2018	S-8	SNNA / Sienna Biopharmaceuticals, Inc. FORM S-8 FORM S-8 As filed with the Securities and Exchange Commission on March 15, 2018 Registration No.
March 15, 2018	EX-99.1	Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results — Pipeline Includes Five Clinical-Stage Programs — Data from Five Clinical Programs Expected, Beginning in 2H18 EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results — Pipeline Includes Five Clinical-Stage Programs — Data from Five Clinical Programs Expected, Beginning in 2H18 WESTLAKE VILLAGE, Calif., Mar. 15, 2018 – Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the fourth quarter and full year of 2017.
March 15, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2018 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporat
March 15, 2018	10-K	SNNA / Sienna Biopharmaceuticals, Inc. FORM 10-K (Annual Report) Form 10-K Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 15, 2018	EX-21.1	List of Subsidiaries. EX-21.1 Exhibit 21.1 List of Subsidiaries of Sienna Biopharmaceuticals, Inc. Name Jurisdiction of Incorporation or Organization Creabilis Holdings Limited United Kingdom Creabilis S.A. Luxembourg Sienna Biopharmaceuticals S.r.L. Italy Creabilis UK Limited United Kingdom Instructive Color, LLC Delaware
February 14, 2018	SC 13G/A	SNNA / Sienna Biopharmaceuticals, Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Sienna Biopharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 82622H108 (CUSIP Number) December 31, 2017 Date of Event Whi
February 2, 2018	SC 13G	SNNA / Sienna Biopharmaceuticals, Inc. / ARCH Venture Fund VIII, L.P. - ARCH VIII - SIENNA BIOPHARMACEUTICALS, INC. 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sienna Biopharmaceuticals, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 82622H108 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 2, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2018 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation
December 27, 2017	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2017 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation) (
November 9, 2017	10-Q	SNNA / Sienna Biopharmaceuticals, Inc. FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 9, 2017	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 Sienna Biopharma 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation
November 9, 2017	EX-99.1	Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results Exhibit 99.1 Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results WESTLAKE VILLAGE, Calif., Nov. 9, 2017 – Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the third quarter of 2017. “We are pleased to report the results of our third quarter,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of
September 7, 2017	EX-99.1	Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results EX-99.1 2 d453816dex991.htm EX-99.1 Exhibit 99.1 Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results WESTLAKE VILLAGE, Calif., Sept. 7, 2017 – Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the second quarter of 2017. “We are pleased to report the results of our second quarter,” said Frederick C. Beddingfield III, M.D., Ph.D., P
September 7, 2017	10-Q	SNNA / Sienna Biopharmaceuticals, Inc. FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00
September 7, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2017 Sienna Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation) (
August 7, 2017	SC 13G	SNNA / Sienna Biopharmaceuticals, Inc. / Partner Fund Management, L.P. - SCHEDULE 13G Passive Investment SC 13G 1 v472507sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Sienna Biopharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 82622H108 (CUSIP Number
August 7, 2017	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 v472507ex99-1.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Sienna Biopharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities E
August 1, 2017	EX-99.2(A)	2017 Incentive Award Plan. Exhibit 99.2(a) SIENNA BIOPHARMACEUTICALS, INC. 2017 INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Sienna Biopharmaceuticals, Inc. 2017 Incentive Award Plan (as it may be amended or restated from time to time, the ?Plan?) is to promote the success and enhance the value of Sienna Biopharmaceuticals, Inc. (the ?Company?) by linking the individual interests of the members of the Board, E
August 1, 2017	EX-99.1	Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Exhibit 99.1 Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares WESTLAKE VILLAGE, Calif., Aug. 1, 2017 ? Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the closing of the Company?s initial public offering of 4,983,333 shares of common stock at a public offering price of $15.00 per share, whic
August 1, 2017	EX-99.3	2017 Employee Stock Purchase Plan. Exhibit 99.3 SIENNA BIOPHARMACEUTICALS, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN 1.1 Purpose and Scope. The purpose of the Sienna Biopharmaceuticals, Inc. 2017 Employee Stock Purchase Plan, as it may be amended from time to time, (the ?Plan?) is to assist employees of Sienna Biopharmaceuticals, Inc., a Delaware corporation, (the ?Company?) and
August 1, 2017	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2017 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38155 27-3364627 (State or other jurisdiction of incorporation) (Com
August 1, 2017	EX-3.1	Amended and Restated Certificate of Incorporation, as amended. Exhibit 3.1 SIENNA BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Sienna Biopharmaceuticals, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law, hereby certifies as follows: The name of the Corporation is Sienna Biopharmaceuticals, Inc. The original Certificate of Incorporation of the corporation was filed with the Sec
August 1, 2017	EX-3.2	Amended and Restated Bylaws. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SIENNA BIOPHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCE
August 1, 2017	EX-99.1(A)	2010 Equity Incentive Plan, as amended. Exhibit 99.1(a) SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.) 2010 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permi
August 1, 2017	S-8	As filed with the Securities and Exchange Commission on August 1, 2017 As filed with the Securities and Exchange Commission on August 1, 2017 Registration No.
July 27, 2017	424B4	4,333,333 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-219142 Prospectus 4,333,333 Shares Common Stock This is Sienna Biopharmaceuticals, Inc.’s initial public offering. We are selling 4,333,333 shares of our common stock. The initial public offering price is $15.00 per share. Currently, no public market exists for our common stock. Our common stock has been approved for listing o
July 24, 2017	S-1/A	As filed with the Securities and Exchange Commission on July 24, 2017 Table of Contents As filed with the Securities and Exchange Commission on July 24, 2017 Registration No.
July 24, 2017	CORRESP	Sienna Biopharmaceuticals, Inc. 30699 Russell Ranch Road, Suite 140 Westlake Village, CA 91362 CORRESP Sienna Biopharmaceuticals, Inc. 30699 Russell Ranch Road, Suite 140 Westlake Village, CA 91362 July 24, 2017 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Suzanne Hayes, Assistant Director Mary Beth Breslin, Legal Branch Chief Johnny Gharib, Senior Counsel Sharon Blume, Account
July 24, 2017	CORRESP	July 24, 2017 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 July 24, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director Mary Beth Breslin, Legal Branch Chief Johnny Gharib, Senior Counsel Sharon Blume,
July 18, 2017	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SIENNA BIOPHARMACEUTICALS, INC. (Exact name o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SIENNA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-3364627 (State of incorporation or organization) (I.R.S. Employer Identification No.) 30699 Russ
July 17, 2017	EX-10.13	Non-Employee Director Compensation Program. Exhibit 10.13 SIENNA BIOPHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Sienna Biopharmaceuticals, Inc. (the ?Company?) Non-Employee Director Compensation Program (this ?Program?) has been adopted under the Company?s 2017 Incentive Award Plan (the ?Plan?) and shall be effective upon the closing of the Company?s initial public offering of its common stock (the ?IPO?). The Equi
July 17, 2017	EX-10.15	SIENNA BIOPHARMACEUTICALS, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN Exhibit 10.15 SIENNA BIOPHARMACEUTICALS, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN 1.1 Purpose and Scope. The purpose of the Sienna Biopharmaceuticals, Inc. 2017 Employee Stock Purchase Plan, as it may be amended from time to time, (the ?Plan?) is to assist employees of Sienna Biopharmaceuticals, Inc., a Delaware corporation, (the ?Company?) an
July 17, 2017	EX-10.6(D)	Form of Restricted Stock Unit Award Grant Notice under the 2017 Incentive Award Plan. Exhibit 10.6(d) SIENNA BIOPHARMACEUTICALS, INC. 2017 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Sienna Biopharmaceuticals, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2017 Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?), an award of restricted stock units (?Restricted Stock Units? or
July 17, 2017	EX-10.6(C)	Form of Restricted Stock Award Grant Notice under the 2017 Incentive Award Plan. Exhibit 10.6(c) SIENNA BIOPHARMACEUTICALS, INC. 2017 INCENTIVE AWARD PLAN RESTRICTED STOCK AWARD GRANT NOTICE Sienna Biopharmaceuticals, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2017 Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?) the number of shares of the Company?s Common Stock set forth below (t
July 17, 2017	EX-3.2	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SIENNA BIOPHARMACEUTICALS, INC. Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SIENNA BIOPHARMACEUTICALS, INC. Sienna Biopharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name of this corporation is Sienna Biopharmaceuticals, Inc., and that thi
July 17, 2017	S-1/A	As filed with the Securities and Exchange Commission on July 17, 2017 Table of Contents As filed with the Securities and Exchange Commission on July 17, 2017 Registration No.
July 17, 2017	EX-10.6(B)	Form of Stock Option Grant Notice and Stock Option Agreement under the 2017 Incentive Award Plan. Exhibit 10.6(b) SIENNA BIOPHARMACEUTICALS, INC. 2017 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Sienna Biopharmaceuticals, Inc., a Delaware corporation, (the “Company”), pursuant to its 2017 Incentive Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s Common Stock (t
July 17, 2017	EX-4.2	Form of Common Stock Certificate. Exhibit 4.2 NUMBER SIENNATM BIOPHARMACEUTICALS SHARES SEE REVERSE SIDE FOR CERTAIN DEFINITIONS INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP 82622H 10 8 THIS CERTIFIES THAT is the owner of FULLY PAID AND NON-ASSESSABLE COMMON SHARES, $0.0001 PAR VALUE, OF SIENNA BIOPHARMACEUTICALS, INC. transferable on the books of the Corporation by the holder hereof in person or by Attorney upon sur
July 17, 2017	EX-10.6(A)	SIENNA BIOPHARMACEUTICALS, INC. 2017 INCENTIVE AWARD PLAN ARTICLE 1. Exhibit 10.6(a) SIENNA BIOPHARMACEUTICALS, INC. 2017 INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Sienna Biopharmaceuticals, Inc. 2017 Incentive Award Plan (as it may be amended or restated from time to time, the ?Plan?) is to promote the success and enhance the value of Sienna Biopharmaceuticals, Inc. (the ?Company?) by linking the individual interests of the members of the Board, E
July 17, 2017	EX-1.1	SIENNA BIOPHARMACEUTICALS, INC. Shares of Common Stock Underwriting Agreement EX-1.1 2 d391086dex11.htm EX-1.1 Exhibit 1.1 SIENNA BIOPHARMACEUTICALS, INC. Shares of Common Stock Underwriting Agreement , 2017 J. P. Morgan Securities LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 1
July 17, 2017	EX-10.1	Amended and Restated Exclusive Supply and License Agreement, dated as of April 19, 2017, by and between Sienna Biopharmaceuticals, Inc. and nanoComposix, Inc. Exhibit 10.1 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. AMENDED AND RESTATED EXCLUSIVE SUPPLY AND LICENSE AGREEMENT by and between NANOCOMPOSIX, INC. a California Corporation and SIENNA BIOPHARMACETICALS, INC. a Delaware corporation Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed s
July 11, 2017	CORRESP	FOIA Confidential Treatment Requested Under 17 C.F.R. § 200.83 CORRESP [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
July 3, 2017	EX-3.4	BYLAWS OF SIENNA LABS, INC. July 29, 2010 TABLE OF CONTENTS Page Article I — MEETINGS OF STOCKHOLDERS - 1 - 1.1 Place of Meetings - 1 - 1.2 Annual Meeting - 1 - 1.3 Special Meeting - 1 - 1.4 Notice of Stockholders’ Meetings - 1 - 1.5 Quorum - 2 - 1.6 Exhibit 3.4 BYLAWS OF SIENNA LABS, INC. July 29, 2010 TABLE OF CONTENTS Page Article I ? MEETINGS OF STOCKHOLDERS - 1 - 1.1 Place of Meetings - 1 - 1.2 Annual Meeting - 1 - 1.3 Special Meeting - 1 - 1.4 Notice of Stockholders? Meetings - 1 - 1.5 Quorum - 2 - 1.6 Adjourned Meeting; Notice - 2 - 1.7 Conduct of Business - 2 - 1.8 Voting - 3 - 1.9 Stockholder Action by Written Consent Without a Meetin
July 3, 2017	EX-10.4(A)	Office Lease, dated May 10, 2016, by and between Sienna Biopharmaceuticals, Inc. and Teachers Insurance and Annuity Association of America. Exhibit 10.4(a) OFFICE LEASE by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA for the benefit of its Real Estate Account (?Landlord?) and SIENNA BIOPHARMACEUTICALS, INC. a Delaware corporation (?Tenant?) Dated as of May 10, 2016 LEASE OF PREMISES 1 BASIC LEASE PROVISIONS 1 STANDARD LEASE PROVISIONS 5 1. TERM 5 2. BASE RENT AND SECURITY DEPOSIT 6 3. ADDITIONAL RENT 7 4. IMPROVEM
July 3, 2017	EX-10.5(B)	Form of Stock Option Agreement under 2010 Equity Incentive Plan. Exhibit 10.5(b) SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.) 2010 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2010 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”). I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned Participant has been
July 3, 2017	EX-3.3	SIENNA BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION EX-3.3 4 d391086dex33.htm EX-3.3 Exhibit 3.3 SIENNA BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Sienna Biopharmaceuticals, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law, hereby certifies as follows: The name of the Corporation is Sienna Biopharmaceuticals, Inc. The original Certificate of Incorporation of the c
July 3, 2017	EX-10.14	Form of Indemnification Agreement for directors and officers. Exhibit 10.14 SIENNA BIOPHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is effective as of [Date] by and between Sienna Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?), and [ ] (?Indemnitee?). A. The Company recognizes the difficulty in obtaining liability insurance for its directors, officers, employees, controlling persons, fiduc
July 3, 2017	EX-10.10	Employment Agreement by and between Sienna Biopharmaceuticals, Inc. and Diane Stroehmann, dated as of July 26, 2017. Exhibit 10.10 SIENNA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), is made by and between Sienna Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Diane Stroehmann (?Executive? and, together with the Company, the ?Parties?), effective as of the date the Company?s registration statement relating to the initial public offering of the Co
July 3, 2017	EX-10.2	Letter Agreement, dated as of October 8, 2015, by and among Sienna Biopharmaceuticals, Inc. and certain of its stockholders listed therein. Exhibit 10.2 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. Sienna Labs, Inc. 2111 Palomar Airport Road, Suite 120 Carlsbad, CA 92011 October 8, 2015 To the stockholders of Sienna Labs, Inc. (the ?Company?) listed on Schedule A hereto (the ?Stockholders?) Re: Side Letter Agreement Ladies and Gentlemen: This letter agreement (the ?Agreement?) is to confirm that in connection wi
July 3, 2017	EX-10.3	Amended and Restated Investors’ Rights Agreement, dated April 12, 2017, by and among Sienna Biopharmaceuticals, Inc. and the investors listed therein. Exhibit 10.3 Execution Version SIENNA BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT April 12, 2017 TABLE OF CONTENTS Page 1. Definitions 2 2. Registration Rights 5 2.1 Demand Registration 5 2.2 Company Registration 7 2.3 Underwriting Requirements 7 2.4 Obligations of the Company 8 2.5 Furnish Information 10 2.6 Expenses of Registration 10 2.7 Delay of Registration 10 2.
July 3, 2017	EX-10.4(B)	First Amendment to Office Lease, dated June 13, 2017, by and between Sienna Biopharmaceuticals, Inc. and Teachers Insurance and Annuity Association of America. Exhibit 10.4(b) FIRST AMENDMENT TO OFFICE LEASE This First Amendment to Office Lease (this “First Amendment”) is made and entered into by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA, for the benefit of its real estate account (“Landlord”), and SIENNA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Tenant”), and shall be effective for all purposes as of the date on which Te
July 3, 2017	EX-21.1	List of Subsidiaries of Sienna Biopharmaceuticals, Inc. Name Jurisdiction of Incorporation or Organization Creabilis Holdings Limited United Kingdom Creabilis S.A. Luxembourg Sienna Biopharmaceuticals S.r.L. Italy Creabilis UK Limited United Kingdom Exhibit 21.1 List of Subsidiaries of Sienna Biopharmaceuticals, Inc. Name Jurisdiction of Incorporation or Organization Creabilis Holdings Limited United Kingdom Creabilis S.A. Luxembourg Sienna Biopharmaceuticals S.r.L. Italy Creabilis UK Limited United Kingdom Instructive Color, LLC Delaware
July 3, 2017	EX-10.7	Employment Agreement by and between Sienna Biopharmaceuticals, Inc. and Frederick C. Beddingfield III, dated as of July 26, 2017. EX-10.7 15 d391086dex107.htm EX-10.7 Exhibit 10.7 SIENNA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), is made by and between Sienna Biopharmaceuticals, Inc., a Delaware corporation (the “Company”) and Frederick Beddingfield, III, M.D., Ph.D. (“Executive” and, together with the Company, the “Parties”), effective as of the date the Company’s registration
July 3, 2017	EX-10.5(A)	SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.) 2010 EQUITY INCENTIVE PLAN EX-10.5(A) 12 d391086dex105a.htm EX-10.5(A) Exhibit 10.5(a) SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.) 2010 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the succe
July 3, 2017	EX-10.11	Employment Agreement by and between Sienna Biopharmaceuticals, Inc. and Todd Harris, dated as of July 26, 2017. Exhibit 10.11 SIENNA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), is made by and between Sienna Biopharmaceuticals, Inc., a Delaware corporation (the “Company”) and Todd Harris (“Executive” and, together with the Company, the “Parties”), effective as of the date the Company’s registration statement relating to the initial public offering of the Company
July 3, 2017	EX-3.5	AMENDED AND RESTATED BYLAWS OF SIENNA BIOPHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF SIENNA BIOPHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCE
July 3, 2017	EX-2.1	Share Purchase Agreement, dated December 6, 2016, by and among Sienna Biopharmaceuticals, Inc., Shareholder Representative Services LLC and the Vendors set forth on Schedule 1 thereto. Exhibit 2.1 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 6 December 2016 THE VENDORS details of whom are set out in Schedule 1 (as Vendors) and SIENNA BIOPHARMACEUTICALS, INC. (as Purchaser) and SHAREHOLDER REPRESENTATIVE SERVICES LLC (as Vendors? Representative) SHARE PURCHASE AGREEMENT related to CREABILIS PLC 99 Bishopsgate London EC2M 3XF United Kingdom Tel: +44.20.7710.
July 3, 2017	EX-10.9	Employment Agreement by and between Sienna Biopharmaceuticals, Inc. and Timothy K. Andrews, dated as of July 26, 2017. Exhibit 10.9 SIENNA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), is made by and between Sienna Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Timothy Andrews (?Executive? and, together with the Company, the ?Parties?), effective as of the date the Company?s registration statement relating to the initial public offering of the Comp
July 3, 2017	EX-10.5(C)	Form of Stock Purchase Right Grant Notice and Restricted Stock Purchase Agreement under 2010 Equity Incentive Plan. Exhibit 10.5(c) SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.) 2010 EQUITY INCENTIVE PLAN STOCK PURCHASE RIGHT GRANT NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENT Pursuant to its 2010 Equity Incentive Plan (the ?Plan?), Sienna Biopharmaceuticals, Inc., a Delaware corporation (f/k/a Sienna Labs, Inc., the ?Company?), hereby grants to the Purchaser listed below (?Purchaser?), the right t
July 3, 2017	EX-10.8	Employment Agreement by and between Sienna Biopharmaceuticals, Inc. and Richard Peterson, dated as of July 26, 2017. Exhibit 10.8 SIENNA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), is made by and between Sienna Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Richard D. Peterson (?Executive? and, together with the Company, the ?Parties?), effective as of the date the Company?s registration statement relating to the initial public offering of the
July 3, 2017	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SIENNA BIOPHARMACEUTICALS, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SIENNA BIOPHARMACEUTICALS, INC. Sienna Biopharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name of this corporation is Sienna Biopharmaceuticals, Inc., and that thi
July 3, 2017	S-1	As filed with the Securities and Exchange Commission on July 3, 2017 Table of Contents As filed with the Securities and Exchange Commission on July 3, 2017 Registration No.
July 3, 2017	EX-10.1	Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. AMENDED AND RESTATED EXCLUSIVE SUPPLY AND LICENSE AGREEMENT by and between NANOCOMPOSIX, INC. a California Corporation SIENNA BIOPHARMACETICALS, INC. a Delaware corporation confident Exhibit 10.1 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. AMENDED AND RESTATED EXCLUSIVE SUPPLY AND LICENSE AGREEMENT by and between NANOCOMPOSIX, INC. a California Corporation and SIENNA BIOPHARMACETICALS, INC. a Delaware corporation Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed s
July 3, 2017	EX-10.12	Employment Agreement by and between Sienna Biopharmaceuticals, Inc. and Paul Lizzul, dated as of July 26, 2017. Exhibit 10.12 SIENNA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), is made by and between Sienna Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Paul F. Lizzul (?Executive? and, together with the Company, the ?Parties?), effective as of the date the Company?s registration statement relating to the initial public offering of the Comp
June 19, 2017	DRS/A	Confidential Draft No. 2 submitted to the Securities and Exchange Commission on June 19, 2017. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains conf Draft Registration Statement No. 2 Table of Contents Confidential Draft No. 2 submitted to the Securities and Exchange Commission on June 19, 2017. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
June 19, 2017	DRSLTR	* * * 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES June 19, 2017 VIA EDGAR AND HAND DELIVERY United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Barcelona Beijing Boston Brussels Century City Chicago Dubai Düsseldorf Frankfurt Hamburg Hong Kong Houston
May 15, 2017	EX-10	SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.) 2010 EQUITY INCENTIVE PLAN Exhibit 10.5(a) SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.) 2010 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permi
May 15, 2017	EX-3	BYLAWS OF SIENNA LABS, INC. July 29, 2010 TABLE OF CONTENTS Page Article I — MEETINGS OF STOCKHOLDERS - 1 - 1.1 Place of Meetings - 1 - 1.2 Annual Meeting - 1 - 1.3 Special Meeting - 1 - 1.4 Notice of Stockholders’ Meetings - 1 - 1.5 Quorum - 2 - 1.6 Exhibit 3.3 BYLAWS OF SIENNA LABS, INC. July 29, 2010 TABLE OF CONTENTS Page Article I ? MEETINGS OF STOCKHOLDERS - 1 - 1.1 Place of Meetings - 1 - 1.2 Annual Meeting - 1 - 1.3 Special Meeting - 1 - 1.4 Notice of Stockholders? Meetings - 1 - 1.5 Quorum - 2 - 1.6 Adjourned Meeting; Notice - 2 - 1.7 Conduct of Business - 2 - 1.8 Voting - 3 - 1.9 Stockholder Action by Written Consent Without a Meetin
May 15, 2017	EX-21	List of Subsidiaries of Sienna Biopharmaceuticals, Inc. Name Jurisdiction of Incorporation or Organization Creabilis Holdings Limited United Kingdom Creabilis S.A. Luxembourg Sienna Biopharmaceuticals S.r.L. Italy Creabilis UK Limited United Kingdom Exhibit 21.1 List of Subsidiaries of Sienna Biopharmaceuticals, Inc. Name Jurisdiction of Incorporation or Organization Creabilis Holdings Limited United Kingdom Creabilis S.A. Luxembourg Sienna Biopharmaceuticals S.r.L. Italy Creabilis UK Limited United Kingdom Instructive Color, LLC Delaware
May 15, 2017	COVER	140 Scott Drive 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES May 15, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Barcelona Beijing Boston Brussels Century City Chicago Dubai D?sseldorf Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid M
May 15, 2017	EX-2	Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 6 December 2016 THE VENDORS details of whom are set out in Schedule 1 (as Vendors) SIENNA BIOPHARMACEUTICALS, INC. (as Purchaser) SHAREHOLDER REPRESENTATIVE SERVICES LLC (as Vendors’ Exhibit 2.1 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 6 December 2016 THE VENDORS details of whom are set out in Schedule 1 (as Vendors) and SIENNA BIOPHARMACEUTICALS, INC. (as Purchaser) and SHAREHOLDER REPRESENTATIVE SERVICES LLC (as Vendors? Representative) SHARE PURCHASE AGREEMENT related to CREABILIS PLC 99 Bishopsgate London EC2M 3XF United Kingdom Tel: +44.20.7710.
May 15, 2017	EX-10	Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. AMENDED AND RESTATED EXCLUSIVE SUPPLY AND LICENSE AGREEMENT by and between NANOCOMPOSIX, INC. a California Corporation SIENNA BIOPHARMACETICALS, INC. a Delaware corporation confident Exhibit 10.1 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. AMENDED AND RESTATED EXCLUSIVE SUPPLY AND LICENSE AGREEMENT by and between NANOCOMPOSIX, INC. a California Corporation and SIENNA BIOPHARMACETICALS, INC. a Delaware corporation Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed s
May 15, 2017	EX-10	SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.) 2010 EQUITY INCENTIVE PLAN STOCK PURCHASE RIGHT GRANT NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENT EX-10 11 filename11.htm Exhibit 10.5(c) SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.) 2010 EQUITY INCENTIVE PLAN STOCK PURCHASE RIGHT GRANT NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENT Pursuant to its 2010 Equity Incentive Plan (the “Plan”), Sienna Biopharmaceuticals, Inc., a Delaware corporation (f/k/a Sienna Labs, Inc., the “Company”), hereby grants to the Purchaser listed below (“
May 15, 2017	EX-10	Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. Sienna Labs, Inc. 2111 Palomar Airport Road, Suite 120 Carlsbad, CA 92011 EX-10 6 filename6.htm Exhibit 10.2 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. Sienna Labs, Inc. 2111 Palomar Airport Road, Suite 120 Carlsbad, CA 92011 October 8, 2015 To the stockholders of Sienna Labs, Inc. (the “Company”) listed on Schedule A hereto (the “Stockholders”) Re: Side Letter Agreement Ladies and Gentlemen: This letter agreement (the “Agreement”) is to confirm
May 15, 2017	EX-10	OFFICE LEASE by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA for the benefit of its Real Estate Account SIENNA BIOPHARMACEUTICALS, INC. a Delaware corporation Dated as of May 10, 2016 LEASE OF PREMISES 1 BASIC LEASE PROVISIONS 1 EX-10 8 filename8.htm Exhibit 10.4 OFFICE LEASE by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA for the benefit of its Real Estate Account (“Landlord”) and SIENNA BIOPHARMACEUTICALS, INC. a Delaware corporation (“Tenant”) Dated as of May 10, 2016 LEASE OF PREMISES 1 BASIC LEASE PROVISIONS 1 STANDARD LEASE PROVISIONS 5 1. TERM 5 2. BASE RENT AND SECURITY DEPOSIT 6 3. ADDITIONAL
May 15, 2017	DRS	Confidential Draft submitted to the Securities and Exchange Commission on May 15, 2017. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains confidentia DRS 1 filename1.htm Table of Contents Confidential Draft submitted to the Securities and Exchange Commission on May 15, 2017. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGIST
May 15, 2017	EX-10	SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.) 2010 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Exhibit 10.5(b) SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.) 2010 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2010 Equity Incentive Plan (the ?Plan?) shall have the same defined meanings in this Stock Option Agreement (the ?Option Agreement?). I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned Participant has been
May 15, 2017	EX-3	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SIENNA BIOPHARMACEUTICALS, INC. EX-3 3 filename3.htm Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SIENNA BIOPHARMACEUTICALS, INC. Sienna Biopharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That the name of this corporation is Sienna Biopharmaceutical
May 15, 2017	EX-10	SIENNA BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT April 12, 2017 TABLE OF CONTENTS Page 1. Definitions 5 2. Registration Rights 8 2.1 Demand Registration 8 2.2 Company Registration 10 2.3 Underwriting Requirements 10 2. EX-10.3 Exhibit 10.3 Execution Version SIENNA BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT April 12, 2017 TABLE OF CONTENTS Page 1. Definitions 5 2. Registration Rights 8 2.1 Demand Registration 8 2.2 Company Registration 10 2.3 Underwriting Requirements 10 2.4 Obligations of the Company 12 2.5 Furnish Information 13 2.6 Expenses of Registration 14 2.7 Delay of Registr

SNNAQ / Sienna Biopharmaceuticals, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)